Recent Publications

Fuller, M.T., Dadoo, O., Xiong, T., Chivukula, P., MacDonald, M.E., Lee, S.K., Austin, R.C., Igdoura, S.A., and Trigatti, B.L. (2022). Extensive diet-induced atherosclerosis in scavenger receptor class B type 1-deficient mice is associated with substantial leukocytosis and elevated vascular cell adhesion molecule-1 expression in coronary artery endothelium. Front Physiol 13, 1023397. 10.3389/fphys.2022.1023397.

Kluck, G.E.G., Qian, A.S., Sakarya, E.H., Quach, H., Deng, Y.D., and Trigatti, B.L. (2023). Apolipoprotein A1 Protects Against Necrotic Core Development in Atherosclerotic Plaques: PDZK1-Dependent High-Density Lipoprotein Suppression of Necroptosis in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 43, 45–63. doi: 10.1161/ATVBAHA.122.318062

Kluck, G.E.G., Yoo, J. A., Sakarya, E.H., and Trigatti, B.L. (2021). Good Cholesterol Gone Bad? HDL and COVID-19. International Journal of Molecular Sciences, 22, 10182. doi:10.3390/ijms221910182

Xiong, T., Qian, A.S., and Trigatti, B.L. (2021). The local effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) on the inflammatory atheroma: beyond LDL cholesterol lowering. Vessel Plus, 5(5). doi: 10.20517/2574-1209.2020.71

Kluck, G.E.G, Durham, K. K., Yoo, J. A., & Trigatti, B. L. (2020). High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity. Frontiers in cardiovascular medicine, 7, 65. doi: 10.3389/fcvm.2020.00065

Rodriguez, A., Trigatti, B. L., Mineo, C., Knaack, D., Wilkins, J. T., Sahoo, D., Asztalos, B. F., Mora, S., Cuchel, M., Pownall, H. J., Rosales, C., Bernatchez, P., Ribeiro Martins da Silva, A., Getz, G. S., Barber, J. L., Shearer, G. C., Zivkovic, A. M., Tietge, U., Sacks, F. M., Connelly, M. A., … Martel, C. (2019). Proceedings of the Ninth HDL (High-Density Lipoprotein) Workshop: Focus on Cardiovascular Disease. Arteriosclerosis, thrombosis, and vascular biology, 39(12), 2457–2467. doi: 10.1161/ATVBAHA.119.313340 

Sokeechand, B., & Trigatti, B. L. (2019). Un-JAMming atherosclerotic arteries: JAM-L as a target to attenuate plaque development. Clinical science (London, England : 1979), 133(14), 1581–1585. doi: 10.1042/CS20190541

Durham, K. K., Kluck, G.E.G, Mak, K. C., Deng, Y. D., & Trigatti, B. L. (2019). Treatment with apolipoprotein A1 protects mice against doxorubicin-induced cardiotoxicity in a scavenger receptor class B, type I-dependent manner. American journal of physiology. Heart and circulatory physiology, 316(6), H1447–H1457. doi: 10.1152/ajpheart.00432.2018

Gonzalez, L., MacDonald, M. E., Deng, Y. D., & Trigatti, B. L. (2018). Hyperglycemia Aggravates Diet-Induced Coronary Artery Disease and Myocardial Infarction in SR-B1-Knockout/ApoE-Hypomorphic Mice. Frontiers in physiology, 9, 1398. doi: 10.3389/fphys.2018.01398

Yu, P., Qian, A. S., Chathely, K. M., & Trigatti, B. L. (2018). Data on leukocyte PDZK1 deficiency affecting macrophage apoptosis but not monocyte recruitment, cell proliferation, macrophage abundance or ER stress in atherosclerotic plaques of LDLR deficient mice. Data in brief, 19, 1148–1161. doi: 10.1016/j.dib.2018.05.128

Yu, P., Qian, A. S., Chathely, K. M., & Trigatti, B. L. (2018). PDZK1 in leukocytes protects against cellular apoptosis and necrotic core development in atherosclerotic plaques in high fat diet fed ldl receptor deficient mice. Atherosclerosis, 276, 171–181. doi: 10.1016/j.atherosclerosis.2018.05.009

Durham, K. K., Chathely, K. M., & Trigatti, B. L. (2018). High-density lipoprotein protects cardiomyocytes against necrosis induced by oxygen and glucose deprivation through SR-B1, PI3K, and AKT1 and 2. The Biochemical journal, 475(7), 1253–1265. doi: 10.1042/BCJ20170703 

Yu, P., Xiong, T., Tenedero, C. B., Lebeau, P., Ni, R., MacDonald, M. E., Gross, P. L., Austin, R. C., & Trigatti, B. L. (2018). Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering. Arteriosclerosis, thrombosis, and vascular biology, 38(1), 26–39. doi: 10.1161/ATVBAHA.117.305140

Durham, K. K., Chathely, K. M., Mak, K. C., Momen, A., Thomas, C. T., Zhao, Y. Y., MacDonald, M. E., Curtis, J. M., Husain, M., & Trigatti, B. L. (2018). HDL protects against doxorubicin-induced cardiotoxicity in a scavenger receptor class B type 1-, PI3K-, and Akt-dependent manner. American journal of physiology. Heart and circulatory physiology, 314(1), H31–H44. doi: 10.1152/ajpheart.00521.2016